Natixis Makes New $727,000 Investment in Medpace Holdings, Inc. (NASDAQ:MEDP)

Natixis bought a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) during the first quarter, Holdings Channel reports. The institutional investor bought 1,800 shares of the company’s stock, valued at approximately $727,000.

Several other hedge funds also recently modified their holdings of MEDP. Bessemer Group Inc. grew its position in Medpace by 1.6% in the 1st quarter. Bessemer Group Inc. now owns 394,834 shares of the company’s stock worth $159,572,000 after purchasing an additional 6,137 shares in the last quarter. Clearbridge Investments LLC grew its holdings in shares of Medpace by 302.4% in the first quarter. Clearbridge Investments LLC now owns 260,411 shares of the company’s stock valued at $105,245,000 after acquiring an additional 195,698 shares in the last quarter. Seven Eight Capital LP bought a new stake in Medpace during the first quarter worth $2,795,000. O Shaughnessy Asset Management LLC purchased a new position in Medpace in the first quarter worth $307,000. Finally, Cynosure Group LLC bought a new position in Medpace in the 1st quarter valued at $613,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. TD Cowen lowered their target price on Medpace from $452.00 to $434.00 and set a “buy” rating on the stock in a research note on Wednesday. William Blair reissued an “outperform” rating on shares of Medpace in a research report on Tuesday. Jefferies Financial Group raised Medpace from a “hold” rating to a “buy” rating and upped their price target for the company from $340.00 to $450.00 in a research report on Tuesday, April 23rd. Guggenheim decreased their price objective on Medpace from $464.00 to $432.00 and set a “buy” rating for the company in a report on Wednesday. Finally, StockNews.com raised shares of Medpace from a “hold” rating to a “buy” rating in a report on Tuesday. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $424.14.

Medpace Stock Performance

Medpace stock traded up $1.59 during midday trading on Friday, hitting $382.09. 12,750 shares of the company’s stock were exchanged, compared to its average volume of 242,264. The stock has a 50-day moving average price of $404.55 and a two-hundred day moving average price of $381.65. The company has a market cap of $11.84 billion, a P/E ratio of 38.79, a PEG ratio of 1.84 and a beta of 1.36. Medpace Holdings, Inc. has a 52-week low of $227.21 and a 52-week high of $459.77.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, July 22nd. The company reported $2.75 EPS for the quarter, beating the consensus estimate of $2.54 by $0.21. The firm had revenue of $528.10 million for the quarter, compared to analyst estimates of $528.41 million. Medpace had a return on equity of 55.14% and a net margin of 16.74%. The company’s revenue was up 14.6% on a year-over-year basis. During the same period in the prior year, the company earned $1.93 EPS. As a group, sell-side analysts expect that Medpace Holdings, Inc. will post 11.59 earnings per share for the current year.

Insider Buying and Selling

In other Medpace news, CEO August J. Troendle sold 5,695 shares of the company’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $395.49, for a total transaction of $2,252,315.55. Following the completion of the transaction, the chief executive officer now owns 654,656 shares of the company’s stock, valued at approximately $258,909,901.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO August J. Troendle sold 4,782 shares of the company’s stock in a transaction dated Wednesday, May 8th. The shares were sold at an average price of $400.58, for a total value of $1,915,573.56. Following the sale, the chief executive officer now directly owns 716,197 shares of the company’s stock, valued at approximately $286,894,194.26. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO August J. Troendle sold 5,695 shares of Medpace stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $395.49, for a total transaction of $2,252,315.55. Following the completion of the transaction, the chief executive officer now directly owns 654,656 shares of the company’s stock, valued at $258,909,901.44. The disclosure for this sale can be found here. Insiders have sold 29,621 shares of company stock valued at $11,816,852 over the last ninety days. 20.30% of the stock is owned by insiders.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.